Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Using the power of data to future-proof the clinical development industry

Using the data gathered over the past five years to become more resilient to future challenges

- PMLiVE

Webcast: How to improve the patient journey through an effective engagement and activation strategy

Watch part two in a series, Evolving Patient Journeys, in which experts from across Inizio explore why, despite best intentions, patient engagement solutions can fall short of expectations.

Inizio

- PMLiVE

Janssen and AbbVie’s Imbruvica combination recommended by NICE for leukaemia

Approximately 3,800 people in the UK are diagnosed with chronic lymphocytic leukaemia each year

- PMLiVE

MS Awareness Week 2023 runs from 24-30 April with seven UK MS charities joining forces

Approximately 130,000 people in the UK are living with the disease

- PMLiVE

Incyte’s Opzelura cream receives EC approval for non-segmental vitiligo

The decision makes Opzelura the first approved treatment in the EU to address repigmentation in this patient population

EU flag

EMA addresses considerations for single-arm trials as pivotal evidence in regulatory filings

The reflection paper offers suggestions on trial design and strategies for minimising bias

- PMLiVE

The impact of AI on digital health: the fifth industrial revolution

By Matt Lewis

- PMLiVE

Oxford PharmaGenesis wins King’s Award following rapid export growth

Oxford PharmaGenesis has been honoured with the first ever King’s Award for Enterprise, the most prestigious business award in the country.

Oxford PharmaGenesis

- PMLiVE

Novartis announces positive long-term data for relapsing MS treatment Kesimpta

Approximately 85% of MS patients are initially diagnosed with relapsing forms of the disease

- PMLiVE

WHO releases largest global collection of publicly available health inequality data

The repository is composed of nearly 11 million data points across more than 2,000 indicators

- PMLiVE

Positive results for Astellas’ zolbetuximab in gastric cancer published in The Lancet

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

ICR and NeoPhore announce immuno-oncology collaboration to develop new cancer drugs

The partners will evaluate the effect of NeoPhore’s small molecule inhibitors on tumours

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links